Everest Medicines Limited (01952.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 27.80

From 52W high−53.96%

Volume7.45M

Market capHKD 9.28B

P/E (TTM)—

P/S (TTM)3.3x

Div yield—

Key dataSep 18, 2026

Open

HKD 27.80

From 52W high

−53.96%

Volume

7.45M

Market cap

HKD 9.28B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

203.2x

P/E (TTM)

—

RSI (14)

44.6

MomentumView details →

1D Return

+4.71%

YTD Return

−25.42%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

203.2x

EV/Sales

3.3x

P/S (TTM)

3.3x

P/B (TTM)

1.5x

ProfitabilityView details →

Gross Margin

69.83%

Net Margin

−2.24%

EBITDA Margin

1.61%

ROE (TTM)

−1.03%

ROA (TTM)

−0.64%

Asset Turnover

0.29x

GrowthView details →

Revenue YoY

+182.91%

EPS YoY

+92.18%

FCF YoY

−36.85%

Revenue CAGR 3Y

+410.98%

EPS CAGR 3Y

+72.53%

EBITDA YoY

+114.03%

MomentumView details →

1D Return

+4.71%

YTD Return

−25.42%

1Y Return

−52.28%

RSI (14)

44.6

vs 50D SMA

−3.83%

vs 200D SMA

−19.81%

Capital & dividendView details →

Debt/Equity

0.38x

Current Ratio

3.77x

Quick Ratio

3.58x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.02

EPS Surprise

97.85%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 5.05

Avg Surprise (4Q)

97.85%

Rev Surprise

−16.55%

Financials snapshotView financials →

Revenue (TTM)

2.41B

Net Income (TTM)

−53.92M

Op. CF (TTM)

−183.59M

Next earningsApr 1, 2027 →

Latest newsMore news →

China's NMPA Center for Drug Evaluation accepted Everest Medicines' marketing registration application to transfer production of VELSIPITY (etrasimod arginine tablets) from overseas to within China, with priority review granted.4d ago

On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.31d ago

Similar companies

Protagonist Therapeutics, Inc.PTGX 热景生物688068.SH Arrowhead Pharmaceuticals, Inc.ARWR Abivax S.A.ABVX GenFleet Therapeutics (Shanghai) Inc.02595.HK Suzhou Ribo Life Science Co06938.HK Find similar companies →

Latest newsMore news →

China's NMPA Center for Drug Evaluation accepted Everest Medicines' marketing registration application to transfer production of VELSIPITY (etrasimod arginine tablets) from overseas to within China, with priority review granted.4d ago On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.31d ago